Compass Therapeutics (CMPX)
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human...
- Open
- 2.340
- High
- 2.445
- Low
- 2.330
- Prev. Close
- 2.370
- Volume
- 2.55M
- Turnover
- 6.08M
- Avg Price
- 2.386
- Bid/Ask Ratio
- -95.65%
- Amplitude
- 4.85%
- 52wk High
- 6.880
- Volume Ratio
- 0.96
- Turnover Ratio
- 1.92%
Compass Therapeutics Analyst Rating
View moreForecast & Rating
Sep 1, 2026Price forecast
$8.92274.65%
Forecast & RatingStrong buy
15analysts
- Strong buy80.00%
- Buy13.33%
- Hold6.67%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Aug 7 at 06:28 PM
Compass Therapeutics shares are trading higher after Piper Sandler raised its price target on the stock from $4 to $6.
- Earnings Watch · Aug 6 at 11:32 AM
Compass Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0
- PUBT · Aug 6 at 11:31 AM
Compass Therapeutics Q2 2026 net loss widens 26.63% to $25.2 million; R&D expenses rise 19% to $19.6 million
- Global Report · Jul 21 at 09:13 AM
Diverging Micro-Data: What Cross-Sector Q2 Updates Signal for the Broader Economy
